127 related articles for article (PubMed ID: 23394742)
1. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Apr; 145(1-3):125-7. PubMed ID: 23394742
[TBL] [Abstract][Full Text] [Related]
2. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
[TBL] [Abstract][Full Text] [Related]
3. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of Brief Psychiatric Rating Scale scores.
Leucht S; Kane JM; Kissling W; Hamann J; Etschel E; Engel R
Br J Psychiatry; 2005 Oct; 187():366-71. PubMed ID: 16199797
[TBL] [Abstract][Full Text] [Related]
5. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
Levine SZ; Leucht S
Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
[TBL] [Abstract][Full Text] [Related]
6. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
7. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
Leucht S; Barabássy Á; Laszlovszky I; Szatmári B; Acsai K; Szalai E; Harsányi J; Earley W; Németh G
Neuropsychopharmacology; 2019 Aug; 44(9):1589-1596. PubMed ID: 30836381
[TBL] [Abstract][Full Text] [Related]
8. Attaining and sustaining remission of predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Jan; 143(1):60-4. PubMed ID: 23218563
[TBL] [Abstract][Full Text] [Related]
9. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
Danion JM; Rein W; Fleurot O
Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
[TBL] [Abstract][Full Text] [Related]
10. Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms.
Levine SZ; Leucht S
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1051-6. PubMed ID: 23228891
[TBL] [Abstract][Full Text] [Related]
11. Linking the PANSS, BPRS, and CGI: clinical implications.
Leucht S; Kane JM; Etschel E; Kissling W; Hamann J; Engel RR
Neuropsychopharmacology; 2006 Oct; 31(10):2318-25. PubMed ID: 16823384
[TBL] [Abstract][Full Text] [Related]
12. Clinical update on amisulpride in deficit schizophrenia.
Rein W; Turjanski S
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S19-27. PubMed ID: 9218164
[TBL] [Abstract][Full Text] [Related]
13. Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia.
Fervaha G; Agid O; Takeuchi H; Lee J; Foussias G; Remington G
J Clin Psychopharmacol; 2015 Apr; 35(2):128-33. PubMed ID: 25679125
[TBL] [Abstract][Full Text] [Related]
14. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
15. What does the PANSS mean?
Leucht S; Kane JM; Kissling W; Hamann J; Etschel E; Engel RR
Schizophr Res; 2005 Nov; 79(2-3):231-8. PubMed ID: 15982856
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
Meskanen K; Ekelund H; Laitinen J; Neuvonen PJ; Haukka J; Panula P; Ekelund J
J Clin Psychopharmacol; 2013 Aug; 33(4):472-8. PubMed ID: 23764683
[TBL] [Abstract][Full Text] [Related]
17. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Müller N; Krause D; Dehning S; Musil R; Schennach-Wolff R; Obermeier M; Möller HJ; Klauss V; Schwarz MJ; Riedel M
Schizophr Res; 2010 Aug; 121(1-3):118-24. PubMed ID: 20570110
[TBL] [Abstract][Full Text] [Related]
19. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
Leucht S; Pitschel-Walz G; Engel RR; Kissling W
Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
[TBL] [Abstract][Full Text] [Related]
20. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia.
Lee J; Fervaha G; Takeuchi H; Powell V; Remington G
J Clin Psychopharmacol; 2015 Jun; 35(3):237-41. PubMed ID: 25839337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
